ValuentumAd

Official PayPal Seal

Johnson & Johnson Raises 2025 Guidance

publication date: Jul 20, 2025
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image Source: J&J. 

Looking to all of 2025, J&J raised its adjusted operational sales growth target to the range of 3.2%-3.7%, up from 2%-3% previously. Adjusted operational earnings per share for the year is expected in the range of $10.63-$10.73, up from $10.50-$10.70 previously, implying growth of 6.5%-7.5% versus the prior year. In the press release, management noted “significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA.”  We like J&J, but don’t include shares in any newsletter portfolio.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.